Answers are grounded in this paper and cite their sources.
Colorectal cancer (CRC) represents a major global health burden, ranking as the third most common malignancy. The transition from benign polyps to metastatic CRC highlights the need for novel therapeutic strategies. Advances in epidemiology and molecular biology have enhanced our understanding of CRC risk factors and tumor dynamics, supporting precision medicine to improve patient outcomes. This review analyzes CRC through epidemiology, molecular mechanisms, and therapeutic innovations, emphasizing advanced drug delivery systems for precision targeted treatment and the shift from conventional to individualized oncology. Key biomarkers such as kirsten rat sarcoma (KRAS) viral oncogene homolog, neuroblastoma RAS (NRAS) viral oncogene homolog, B-Raf proto-oncogene (BRAF), human epidermal growth factor (HER2), neurotrophic tyrosine receptor kinase (NTRK) and microsatellite instability (MSI)-H play crucial role in guiding treatment. Despite the potential of targeted therapies, obstacles including tumor microenvironment and resistance still exist. Emerging nanoparticle and lipid-based systems may address these challenges. Future research should focus on clinical translation, optimizing delivery methods, and identifying new biomarkers to enhance personalized CRC treatment.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: